Printed from Voxsanity (voxsanity.com.au) — NCT03696680 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Brain Cancer
Phase 2 Brain Cancer Trial, Recruiting
NCT03696680
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are older than 18 years of age
- You are generally well enough to carry out normal daily activities with little or no limitation (confirm with trial site)
- You have fewer than 4 brain metastases (cancer that has spread to the brain from another part of the body, such as melanoma or another solid tumour), confirmed by a tissue sample; this includes patients who have had surgery to remove a brain metastasis and have 1 to 3 remaining
- Your brain tumour(s) measure between 5 and 30 mm across
- A specialist medical team has agreed that you are suitable for a precise, targeted form of radiotherapy called stereotactic radiotherapy
- At least one of your brain lesions shows signs of bleeding inside the tumour, visible on specific brain scans (CT or MRI)
- There is no sign that the cancer has spread to the lining of the brain or spinal cord
- None of your brain metastases are located in the brainstem
- Your overall health score related to your type of cancer meets a minimum level set by the trial (confirm with trial site, or check at brainmetgpa.com)
- You are not currently receiving cancer treatments such as chemotherapy, hormone therapy, or certain targeted therapies during radiotherapy (these must be paused at least 7 days before and 7 days after treatment; immunotherapy does not need to be paused)
- Your doctor estimates you are likely to live for more than 6 months
- You are able to cooperate with wearing a custom-fitted mask during treatment
- You are able to understand and follow the requirements of the study
- You are covered by a social security or health insurance scheme
- You have given written consent to take part
Who may not be able to join:
- You have small cell lung cancer, germ cell tumours, lymphoma, leukaemia, or multiple myeloma
- You have a condition affecting the brain or nervous system that causes it to gradually deteriorate (such as Parkinson's or Alzheimer's disease)
- You have symptoms unrelated to your cancer that require long-term use of steroid medication
- You cannot have an MRI scan or receive the contrast dye (gadolinium) used during MRI
- You have a bleeding or clotting disorder that is not related to bleeding within the brain tumour(s)
- You have a condition that makes your body unusually sensitive to radiation (for example, Neurofibromatosis)
- Your platelet count (cells that help blood clot) is below 100,000 per mm³
- You are taking blood-thinning or anti-clotting medication during radiotherapy, unless it can safely be stopped for at least 5 days before treatment and restarted 2 weeks after treatment ends
- You have bleeding metastases located in the brainstem
- Your treatment plan would deliver a significant dose of radiation to other metastases at the same time (confirm with trial site)
- You have previously had stereotactic radiotherapy to the brain
- You have previously had whole-brain radiotherapy
- There are geographical, social, or psychological factors that might make it difficult for you to fully participate in the study
- You are already taking part in another clinical trial that could interfere with this one
- You are under legal guardianship or have had your liberty restricted
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.
Contact this trial
Phone: 0231455020
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Recruiting
Phase
Phase 2
Sponsor
Centre Francois Baclesse
Registry
ClinicalTrials.gov
Start date
16 January 2019
Est. completion
1 June 2027
Where this trial is recruiting
🇫🇷 France
Primary endpoints
Hemorrhagic complication rate (new hemorrhage or increase of hemorrhage); Local tumoral response rate defined according to the recommendations of the RECIST criteria
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.